CTMX Company Profile and Key Details
CytomX Therapeutics
Price Chart
Stock Price Today
CytomX Therapeutics, Inc. (CTMX) stock declined over -0.92%, trading at $3.22 on NASDAQ, down from the previous close of $3.25. The stock opened at $3.26, fluctuating between $3.13 and $3.27 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 27, 2026 | 3.25 | 3.43 | 3.25 | 3.25 | 2.5M |
| Jul 24, 2026 | 3.34 | 3.38 | 3.20 | 3.24 | 1.52M |
| Jul 23, 2026 | 3.31 | 3.41 | 3.28 | 3.33 | 1.38M |
| Jul 22, 2026 | 3.40 | 3.44 | 3.33 | 3.33 | 2.31M |
| Jul 21, 2026 | 3.50 | 3.55 | 3.39 | 3.42 | 5.96M |
| Jul 20, 2026 | 3.65 | 3.74 | 3.51 | 3.52 | 5.54M |
| Jul 17, 2026 | 3.65 | 3.69 | 3.52 | 3.62 | 3.67M |
| Jul 16, 2026 | 3.64 | 3.72 | 3.53 | 3.67 | 4.78M |
| Jul 15, 2026 | 3.64 | 3.71 | 3.53 | 3.68 | 5.15M |
| Jul 14, 2026 | 3.70 | 3.81 | 3.64 | 3.66 | 4.59M |
| Jul 13, 2026 | 3.69 | 3.80 | 3.63 | 3.70 | 3.31M |
| Jul 10, 2026 | 4.00 | 4.02 | 3.62 | 3.76 | 2.99M |
| Jul 09, 2026 | 3.81 | 3.96 | 3.77 | 3.96 | 2.16M |
| Jul 08, 2026 | 3.77 | 3.88 | 3.65 | 3.83 | 3.16M |
| Jul 07, 2026 | 3.86 | 3.89 | 3.69 | 3.84 | 3.19M |
| Jul 06, 2026 | 3.76 | 3.89 | 3.70 | 3.81 | 3.2M |
| Jul 02, 2026 | 3.65 | 3.90 | 3.60 | 3.82 | 5.12M |
| Jul 01, 2026 | 3.76 | 3.82 | 3.58 | 3.60 | 6.42M |
| Jun 30, 2026 | 3.75 | 3.89 | 3.64 | 3.75 | 5.91M |
| Jun 29, 2026 | 3.39 | 3.81 | 3.36 | 3.74 | 6.96M |
Contact Details
About Company
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Company Information
| Employees | 69 |
| Beta | 2.08 |
| Sales or Revenue | $101.21M |
| 5Y Sales Change% | -0.04% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.
Dr. Jamie Moore Ph.D.
Senior Vice President & Head of Protein and Process Sciences and Manufacturing
Dr. Marcia P. Belvin Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Sean A. McCarthy D.Phil., DPHIL
Chairman & Chief Executive Officer
Ms. Leslie Robbins
Senior Vice President of Intellectual Property
Mr. Christopher W. Ogden
Senior Vice President of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer
Ms. Danielle Olander-Moghadassian
Senior Vice President & Chief HR Officer
Mr. Jeffrey Landau B.S., M.B.A.
Senior Vice President, Head of Strategy & Chief Bus. Officer
Dr. Chau Cheng M.B.A., Ph.D.
Vice President of Investor Relations
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep